Stock Screener App

Gratuito -

Installare

Drug Manufacturers - Specialty & Generic

44.88

3.60% 1.56

after-market

Dopo l'orario di chiusura: 44.88

Supernus Pharmaceuticals Inc (SUPN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SUPN Giù? Forum Previsione

Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie

Short Term Trend Reversal in Supernus Pharmaceuticals Inc. PossibleJuly 2025 PostEarnings & Consistent Income Trade Ideas - newsyoung.net

This Insider Has Just Sold Shares In Supernus Pharmaceuticals - simplywall.st

Insider Sell: Bethany Sensenig Sells 5,369 Shares of Supernus Ph - GuruFocus

Supernus Pharmaceuticals stock hits 52-week high at 43.62 USD By Investing.com - Investing.com Australia

Supernus Pharmaceuticals stock hits 52-week high at 43.62 USD - Investing.com

Is Supernus Pharmaceuticals, Inc. exposed to political riskTrade Risk Report & AI Optimized Trade Strategies - mustnews.co.kr

Can Supernus Pharmaceuticals Inc. expand into new markets2025 Dividend Review & Fast Entry High Yield Tips - classian.co.kr

Published on: 2025-08-17 09:07:05 - metal.it

How high can Supernus Pharmaceuticals Inc. stock goJuly 2025 Snapshot & Community Verified Trade Alerts - Newser

Live market analysis of Supernus Pharmaceuticals Inc.July 2025 Movers & High Yield Equity Trading Tips - Newser

What moving averages say about Supernus Pharmaceuticals Inc.Rate Cut & Daily Risk Controlled Trade Plans - Newser

Is Supernus Pharmaceuticals Inc. stock ready for a breakoutMarket Growth Summary & Risk Managed Trade Strategies - Newser

Will Supernus Pharmaceuticals Inc. stock go up soonMarket Rally & Safe Entry Trade Reports - Newser

What makes Supernus Pharmaceuticals Inc. stock price move sharplyProfit Target & Advanced Swing Trade Entry Alerts - Newser

Technical signs of recovery in Supernus Pharmaceuticals Inc.Quarterly Trade Report & Comprehensive Market Scan Insights - Newser

Is Supernus Pharmaceuticals Inc. forming a bottoming baseMarket Performance Recap & Technical Confirmation Trade Alerts - Newser

Is Supernus Pharmaceuticals Inc. the Top Chart Pick This WeekInflation Watch & AI Powered Market Entry Strategies - sundaytimes.kr

Will Supernus Pharmaceuticals Inc. benefit from sector rotationJuly 2025 Movers & Long-Term Safe Investment Plans - newsimpact.co.kr

PNC Financial Services Group Inc. Acquires 726 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Supernus Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowWall Street Watch & Fast Gaining Stock Strategy Reports - Newser

Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance

Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know | FinancialContent - FinancialContent

These Three Healthcare Cos. Could Inject New Life Into an Ailing Portfolio - TheStreet Pro

Analyzing net buyer seller activity in Supernus Pharmaceuticals Inc.2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - Newser

Short Term Trend Reversal in Supernus Pharmaceuticals Inc. Possible [Portfolio Gains Report]Free Daily Stock Momentum Reports - 선데이타임즈

Supernus Pharmaceuticals' Accrual Ratio and Unusual Items Impact Earnings - AInvest

Statutory Profit Doesn't Reflect How Good Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are - Yahoo Finance

SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade - Yahoo Finance

5 Insightful Analyst Questions From Supernus Pharmaceuticals’s Q2 Earnings Call - ca.finance.yahoo.com

Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN

Supernus Pharmaceuticals shares rise 1.48% intraday after Lotus Pharmaceuticals reported a 6% revenue increase in the first half of 2025. - AInvest

Supernus Announces Second Quarter 2025 Financial Results - ADVFN Brasil

How to recover losses in Supernus Pharmaceuticals Inc. stockFree Chart Alert System With Entry Targets - Newser

RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it

Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionShort-Term Support and Resistance Forecast - Newser

CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey

Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks

Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks

SUPN Stock Surge: What’s Driving It? - StocksToTrade

Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - Yahoo Finance

Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada

Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus

Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com

Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Australia

Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest

Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox

Supernus: Q2 Earnings Snapshot - New Haven Register

Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance

Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... By GuruFocus - Investing.com Canada

Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks

Supernus Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat

Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Supernus Pharmaceuticals Delivers Growth With Qelbree And GOCOVRI - Finimize

Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance

Supernus Pharmaceuticals Q2 2025: Navigating Contradictions in ONAPGO, Qelbree, and ZURZUVAE Growth - AInvest

Supernus Pharmaceuticals shares rise 4.21% after-hours after reporting Q2 revenue of $165.5M, beating estimates. - AInvest

Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - TradingView

Supernus Pharmaceuticals Q2 Earnings Rise, Revenue Falls; 2025 Revenue Guidance Boosted - MarketScreener

ALKS

$29.75

2.37%

ELAN

$17.91

2.40%

RDY

$14.51

0.62%

VTRS

$10.65

0.37%

NBIX

$135.43

0.11%

UTHR

$312.23

0.51%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters